InflaRx NV (IFRX)
2.505
+0.04
(+1.42%)
USD |
NASDAQ |
May 18, 16:00
2.46
-0.04
(-1.80%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 368.97M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 38.76% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 2341.74 |
| Price to Book Value | 8.681 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0223 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 98.49% |
Profile
| InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany. |
| URL | http://www.inflarx.de |
| Investor Relations URL | N/A |
| HQ State/Province | Thueringen |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Aug. 06, 2026 (est.) |
| Last Earnings Release | May. 07, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany. |
| URL | http://www.inflarx.de |
| Investor Relations URL | N/A |
| HQ State/Province | Thueringen |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Aug. 06, 2026 (est.) |
| Last Earnings Release | May. 07, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |